Advertisement

Cambridge-based Ligon Discovery today announced a partnership with Bayer Schering Pharma AG of Germany to use Ligon’s Small Molecule Microarray (SMM) screening platform to seek drug candidates for new disease targets.

Ligon said in a press release that its SMM technology offers a new approach to identifying valid drug leads for historically intractable disease targets.

SOURCE

Advertisement
Advertisement